• Can changes in EEG improve neuropathic pain treatments - read Oct newsletter.
  • Nine posters ready to reveal at the SfN virtual conference 8-11 Nov, booth 1818.
  • Joined-up preclinical and clinical trials to advance psilocybin drug development
  • Transpharmation joins HaPpY team to help break the vicious cycle of chronic pain & mood disorders, see News for details
  • Announcing new premises in Poland with a focus on neuropsychiatric disorders...
  • New state-of-the-art premises at Discovery Park, Kent


News you can use


All the latest conference updates; those that we are attending and the studies that we are presenting

WMS virtual conference 28th September – 2nd October 2020


As experts in preclinical neuroscience, we look forward to attending the 25th annual international congress of the World Muscle Society and making contact with other participants. https://www.worldmusclesociety.org/web_pages/view/home Already involved in the EU-funded Brain Involvement in Dystrophinopathies, (BIND) project, our combined research aims at achieving ground-breaking progress in the understanding and treatment of neuropsychiatric comorbidities affecting Duchenne and Becker muscular dystrophy patients. For more information about our work in this particular field please email This email address is being protected from spambots. You need JavaScript enabled to view it.


Start a Conversation

preclinical +44 (0)203 633 2807

clinical trials +353 (0)1896 42 60

clinical research +48 515 244 120

EEG contact@transpharmation.co.uk

Copyright ©2021 Transpharmation Ltd. Website created by Identity Ipswich Web Design